(Reuters) -Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study was unlikely to meet its main goal.

The trial was testing whether the drug, milvexian, could prevent repeat heart problems in patients who recently suffered acute coronary syndrome, a condition that occurs when blood flow to the heart is suddenly blocked, usually by a clot.

Shares of Bristol Myers fell 5% in premarket trading, while J&J slipped slightly.

The decision follows a preplanned interim analysis by the trial’s monitoring committee, which determined the drug was not expected to show a benefit when added to standard antiplatelet therapy. These drugs, such as aspirin or cl

See Full Page